Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 18/20 | 0.83 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864487 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL4868791 | 0.83 | ADRB2 (0.87) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Methane SCHEMBL5000046 | 0.82 | ADRB2 (0.85) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL19329935 | 0.79 | ADRB2 (0.52) | ADRB2TSHRNFKB1HIF1ATDP1 | |
| SCHEMBL9768105 | 0.79 | ADRB2 (0.59) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL4868323 | 0.78 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL4868288 | 0.78 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL15677514 | 0.77 | ADRB2 (0.73) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL9157212 | 0.77 | ADRB2 (0.60) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL7724542 | 0.76 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050261338-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-11-24 | — | — | US | disclosed |
| US-20050209275-A1 | Beta 2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-09-22 | — | — | US | disclosed |
| US-6916961-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20030087307-A1 | Beta2-adrenergic receptor agonists | ADVANCED MEDICINE, INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261338-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885CYP1A2 601/4885 |
| US-20050209275-A1 | Beta 2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885CYP1A2 666/4885 |
| US-20030087307-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885CYP1A2 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.